ATBPF News and Press, Antibe Therapeutics From 02/14/22

- Acute pain clinical program for otenaproxesul initiating this quarter - Ended quarter with a $59 million cash position Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-gener...

Antibe Therapeutics (OTCQX:ATBPF): FQ2 GAAP EPS of -$0.17. As of September 30, 2021, the Company had an available cash balance totaling $60.5M, compared to $72M as at March 31, 2021. For further details see: Antibe Therapeutics reports FQ2 results

- Otenaproxesul’s acute pain clinical program set to begin early next quarter - Ended quarter with a $60 million cash position Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to de...

- Leverages existing extensive clinical data to shorten development path - Acute pain clinical program initiating early next quarter - Third-party commercial studies underway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage comp...

- Acute pain program launched for otenaproxesul - New patent application aimed at extending otenaproxesul’s IP protection into the 2040s - Dosing regimen for osteoarthritis indication requires additional investigation - Company fully funded into ...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23 rd Annual Global I...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held e...

- Ended quarter with a strong $67 million cash position - AME study on required pause; data expected in October Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines ...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conf...

- Current AME study paused in adherence to safety protocol Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption, metabolism ...